Synthetic data — demonstration only. No real patient information.

Sample output: cross-vendor NGS unification.

This sample shows what UNMIRI's NGS Interpretation API produces when given a UNMIRI-rendered synthetic NSCLC sample in Foundation Medicine-style layout. Not a Foundation Medicine document. The same parsing engine handles Tempus, Caris, Guardant, Natera, NeoGenomics, and other vendor formats with a unified output structure. Inside the platform, this same output is what the genomics-aware decision support API consumes upstream, what the free pathologist tool surfaces to clinicians, and what the literature surveillance pipeline indexes against. One parser, one schema, four products built on top. Toggle between the oncologist's view and the raw API response.

EGFR L858RTP53 R175H co-mutationPD-L1 <1%Stage IVA NSCLCFoundation Medicine-format input1.4s processing time
Download sample PDF

UNMIRI

Actionable Insight Report

ID: ins_demo_8xk2mq9p

April 18, 2026 — 09:14:32 UTC

Page 1 of 2

Patient

ID: DEMO-2026-001
Age / Sex: 67 · Female
Diagnosis: Metastatic NSCLC Adenocarcinoma
Stage: Stage IVA (T2a N3 M1b)
Specimen: CT-guided core biopsy — right lower lobe
Platform: FoundationOne CDx (482-gene panel)

Biomarkers

PD-L1 (22C3)

<1%

TMB

4.2 mut/Mb

MSI

MSI-Stable

Actionable Alterations

EGFR L858R

Actionable
Exon 21VAF 34.2%Point mutation

Pathogenic — sensitizing

TP53 R175H

Exon 5VAF 41.1%Point mutation

Pathogenic — co-occurring

Negative findings (selected)

ALK rearrangement — negative

ROS1 rearrangement — negative

MET exon 14 skipping — not detected

RET fusion — negative

+3 more — see source report

Treatment Recommendations — Evidence-graded

CIViC 2026-Q1 · openFDA · FLAURA NEJM 2020

1

Osimertinib (Tagrisso®)

3rd-gen EGFR TKII-AFDA-approved (2018, first-line)

EGFR exon 21 L858R sensitizing mutation. FLAURA trial: OS 38.6 mo vs. 31.8 mo for 1st-gen TKI. AMP/ASCO/CAP Tier I-A evidence; FDA-approved first-line (2018).[C1][C2]

Dosing: 80 mg orally once daily

2

Erlotinib + Ramucirumab

1st-gen EGFR TKI + VEGFR2 inhibitorI-AFDA-approved (2020, first-line)

RELAY trial: PFS 19.4 vs. 12.4 months. FDA-approved specifically for EGFR exon 19 del / L858R first-line (May 2020). Consider where osimertinib tolerability is a concern or in TP53 co-mutated disease.[C1][C3]

Dosing: Erlotinib 150 mg PO daily + Ramucirumab 10 mg/kg IV q14d

3

Carboplatin + Pemetrexed ± Bevacizumab

Platinum doublet chemotherapyStandard-of-careFDA-approved (general NSCLC)

Standard cytotoxic regimen for EGFR TKI-ineligible patients or acquired TKI resistance. TP53 R175H co-mutation may predict earlier TKI resistance, making platinum doublet a reasonable second-line option. Not a biomarker-specific recommendation; AMP/ASCO/CAP tier evidence does not apply.[C1]

Dosing: Carboplatin AUC 5 + Pemetrexed 500 mg/m² IV q21d

Contraindication — High Priority

Checkpoint Inhibitor Monotherapy

Drugs affected: Pembrolizumab · Atezolizumab · Cemiplimab

PD-L1 TPS <1% (Dako 22C3 pharmDx). EGFR-mutant NSCLC responds poorly to single-agent PD-1/PD-L1 checkpoint inhibitors independent of PD-L1 expression: the EGFR-mutant subgroup of KEYNOTE-010 showed no overall-survival benefit from pembrolizumab monotherapy versus docetaxel. Where an immunotherapy-containing regimen is considered, the chemotherapy-plus-antiangiogenic combination supported by the IMpower150 EGFR-mutant subgroup is the evidenced approach, not single-agent checkpoint blockade. Checkpoint inhibitor monotherapy is not indicated.[C1][C4][C6]

Generated by UNMIRI GraphRAG v1.2 · 22 source pages → 2 pages · 1380ms

Not for clinical use without physician review · Continue →

Page 1 of 2

What you just saw

Generated by Engine 1 of the UNMIRI platform. Useful as a reference for healthtech vendors evaluating API capability, biotech medical affairs teams understanding what evidence looks like in citation-grounded form, and pathologists previewing what the free pathologist tool will produce. Every element below is grounded in the structured knowledge graph, not LLM inference.

📊

Evidence-graded recommendations

Each recommendation carries an AMP/ASCO/CAP 2017 tier and FDA-approval status, anchored to the same primary trial publications and FDA labels your oncologists reference manually.

⚠️

Contraindication flagging

The PD-L1 <1% + EGFR mutation combination automatically triggers a high-priority checkpoint inhibitor contraindication, sourced from the knowledge graph.

🔬

Clinical trial matching

MARIPOSA-2 is pre-matched as the anticipated resistance pathway if osimertinib fails, surfaced now rather than at progression, so the oncologist can counsel the patient early. The graph traverses variant → resistance pathway → trial eligibility, not keyword search.

📋

Full citation trail

Every recommendation links back to the FDA label, primary trial publication, and CIViC entry that supports it. Auditable on demand.

Want this capabilityin your product?

The Engine 1 NGS Interpretation API is in active development with design partners. If your healthtech product needs cross-vendor genomic report parsing, we'd love to talk.

Talk to our team about API access →See the platform

All data on this page is synthetic. No real patient information was used.

Related references

Reference

Open FHIR Genomics schema

The data contract that shapes this output. Apache 2.0 on GitHub.

Reference

FHIR Genomics validator

Paste your own synthetic Bundle and check it against the IG.

Case study

EGFR L858R walkthrough

The full parse → tier → CDS path for the same case shown here.

Variant cheat sheet

EGFR mutations in NSCLC

Decision-support reference for what the report above flags.

Product

NGS Interpretation API

What ships this output to your EHR or LIS in production.

Live demo

Vendor sample showcase

Run the parser against the same fixture and watch the JSON appear.